AC Immune SA ACIU
NASDAQ
| 06/30/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1,108.20% | -67.32% | -96.02% | 108.40% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,108.20% | -67.32% | -96.02% | 108.40% | -- |
| Cost of Revenue | -35.00% | -26.02% | -2.41% | 7.63% | 2.07% |
| Gross Profit | 131.19% | 22.82% | -219.22% | -3.42% | 4.27% |
| SG&A Expenses | -5.01% | 15.72% | 2.77% | -6.27% | -13.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -355.06% | -474.84% | -- | 41.06% | 101.41% |
| Total Operating Expenses | -29.77% | -17.96% | -1.24% | 4.80% | -1.33% |
| Operating Income | 106.42% | 14.95% | -333.52% | -1.40% | 6.12% |
| Income Before Tax | 109.23% | -0.03% | -411.58% | -2.06% | -3.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 109.23% | -0.01% | -411.58% | -2.06% | -3.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 109.23% | -0.01% | -411.58% | -2.06% | -3.61% |
| EBIT | 106.42% | 14.95% | -333.52% | -1.40% | 6.12% |
| EBITDA | 108.06% | 15.25% | -317.71% | -1.33% | 6.05% |
| EPS Basic | 108.81% | 1.06% | -413.97% | -0.99% | -2.53% |
| Normalized Basic EPS | 108.84% | 0.98% | -- | -0.95% | -2.57% |
| EPS Diluted | 108.81% | 2.68% | -446.02% | -0.99% | -2.53% |
| Normalized Diluted EPS | 108.84% | 0.98% | -- | -0.95% | -2.57% |
| Average Basic Shares Outstanding | 4.59% | 1.08% | -0.73% | 1.09% | 1.03% |
| Average Diluted Shares Outstanding | 4.59% | 1.08% | -1.73% | 1.09% | 1.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |